CM
REGN icon

Capula Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capula Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$155K Sell
200
-100
-33% -$76.6K ﹤0.01% 813
2025
Q4 		$232K Hold
300
– – ﹤0.01% 560
2025
Q3 		$169K Buy
300
+100
+50% +$56.5K ﹤0.01% 648
2025
Q2 		$105K Buy
+200
New +$112K ﹤0.01% 496
2024
Q4 		– Sell
-200
Closed -$210K – 566
2024
Q3 		$210K Buy
+200
New +$223K ﹤0.01% 368
2023
Q1 		– Sell
-14,200
Closed -$10.2M – 895
2022
Q4 		$10.2M Buy
14,200
+10,100
+246% +$7.45M 0.14% 178
2022
Q3 		$2.82M Buy
+4,100
New +$2.58M 0.04% 341
2022
Q2 		– Sell
-15,000
Closed -$10.5M – 362
2022
Q1 		$10.5M Buy
+15,000
New +$9.49M 0.15% 130
2021
Q2 		– Sell
-900
Closed -$426K – 856
2021
Q1 		$426K Buy
+900
New +$438K 0.01% 396

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capula Management's REGN Position: Q4 2025 in Review

Capula Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 181 shares — an estimated $123K sold.

Capula Management first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $4.39M in Q1 2021. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Capula Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capula Management sold 181 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $123K.
  • Capula Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Capula Management's Regeneron Pharmaceuticals position peaked at $4.39M in Q1 2021.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Capula Management's 13F filing for Q4 2025, filed 13 Feb 2026.